oral glp-1 agonist approved receptor Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients New GLP-1 Pill Foundayo (Orforglipron)
Description
The prevalence of AD is 10% in people over 65 years of age and 40% in people over 85 years of age
Current Food and Drug Administration (FDA)Approved and Investigational GLP-1RAs Exenatide, the first FDA-approved GLP-1RA (2005), showed potential for significant weight loss, though more evidence is needed for use in treating uncomplicated obesity [1619]
Recent policy interventions, such as the Inflation Reduction Act, aimed to expand eligibility for subsidies and cap out-of-pocket costs, but implementation and awareness challenges persist
July 2016
D., Stockmeier C
